Medtronic's EOflow Acquisition Will Not Impact Insulet's Omnipod' Insulin Pump In Near or Medium Term: Analyst
Portfolio Pulse from Vandana Singh
Medtronic has agreed to acquire Korea-based EOflow, manufacturer of the EOPatch insulin delivery device, for $738 million. Analysts at William Blair believe this acquisition will not impact Insulet Corporation's Omnipod insulin pump in the near or medium term.
May 26, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts at William Blair believe Medtronic's acquisition of EOflow will not impact Insulet Corporation's Omnipod insulin pump in the near or medium term.
William Blair analysts believe that Insulet's Omnipod insulin pump will not be affected by Medtronic's acquisition of EOflow in the near or medium term, as the company has strong momentum with the Omnipod 5 launch and long-term catalysts.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Medtronic acquires EOflow for $738 million, expanding its insulin delivery device portfolio.
Medtronic's acquisition of EOflow expands its product offerings in the insulin delivery device market. This could potentially increase its market share and revenue in the long term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100